JP2024546096A - コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 - Google Patents
コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 Download PDFInfo
- Publication number
- JP2024546096A JP2024546096A JP2024533985A JP2024533985A JP2024546096A JP 2024546096 A JP2024546096 A JP 2024546096A JP 2024533985 A JP2024533985 A JP 2024533985A JP 2024533985 A JP2024533985 A JP 2024533985A JP 2024546096 A JP2024546096 A JP 2024546096A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- cspg4
- amino acid
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163286719P | 2021-12-07 | 2021-12-07 | |
| US63/286,719 | 2021-12-07 | ||
| PCT/US2022/052099 WO2023107538A2 (en) | 2021-12-07 | 2022-12-07 | Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546096A true JP2024546096A (ja) | 2024-12-17 |
| JP2024546096A5 JP2024546096A5 (cg-RX-API-DMAC7.html) | 2025-12-09 |
Family
ID=86731156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533985A Pending JP2024546096A (ja) | 2021-12-07 | 2022-12-07 | コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250313648A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444753A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546096A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023107538A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012503203A (ja) * | 2008-09-19 | 2012-02-02 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 基底乳癌腫の診断および処置のためのcspg4に対するモノクローナル抗体 |
| US10093745B2 (en) * | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| EP3218413A4 (en) * | 2014-11-12 | 2018-03-28 | Memorial Sloan-Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| WO2016164429A1 (en) * | 2015-04-06 | 2016-10-13 | The General Hospital Corporation | Anti-cspg4 chimeric antigen receptors |
| AU2019287676A1 (en) * | 2018-06-13 | 2021-01-07 | The General Hospital Corporation | Methods and compositions for chimeric antigen receptor targeting cancer cells |
-
2022
- 2022-12-07 WO PCT/US2022/052099 patent/WO2023107538A2/en not_active Ceased
- 2022-12-07 JP JP2024533985A patent/JP2024546096A/ja active Pending
- 2022-12-07 US US18/717,696 patent/US20250313648A1/en active Pending
- 2022-12-07 EP EP22905067.9A patent/EP4444753A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4444753A4 (en) | 2026-06-24 |
| WO2023107538A3 (en) | 2023-08-03 |
| US20250313648A1 (en) | 2025-10-09 |
| WO2023107538A2 (en) | 2023-06-15 |
| EP4444753A2 (en) | 2024-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113661180B (zh) | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 | |
| CN112512575B (zh) | 双特异性抗体组合物及其使用方法 | |
| US10479997B2 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| CN113164589A (zh) | 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 | |
| CN112673093A (zh) | 靶向flt3、pd-1和/或pd-l1的免疫疗法的组合物和方法 | |
| US12415867B2 (en) | Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof | |
| CN107405362A (zh) | 抗dll3嵌合抗原受体及其使用方法 | |
| CN111108124B (zh) | 新型抗体以及treg消耗性抗体和免疫刺激性抗体的组合使用 | |
| KR20220152220A (ko) | Cd19-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도 | |
| KR20230058442A (ko) | 간세포성 암종에 대한 lag-3 길항제 요법 | |
| TW202321287A (zh) | 特異性靶向間皮素之經工程改造之免疫細胞及其用途 | |
| KR20230058408A (ko) | 암 면역 미세 환경 조절 물질 및 그에 따른 예방·진단·치료적 이용 | |
| WO2025072639A1 (en) | Methods of treating cancer resistant to immune checkpoint therapy and compositions useful for the same | |
| US20260007697A1 (en) | New chimeric antigen receptor (car) cells and medical uses thereof | |
| US20240150470A1 (en) | Lym-1 and lym-2 antibody compositions and improved car constructs | |
| US20250179170A1 (en) | Use of anti-claudin-1 antibodies to increase t cell availability | |
| US20250313648A1 (en) | Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides | |
| CN120380023A (zh) | 用于癌症治疗的纳米抗体 | |
| JP2015517655A (ja) | Bリンパ性悪性疾患を治療するための組成物および方法 | |
| US20240165228A1 (en) | Targeted inhibition of dkk3 to sensitize tumors to immunotherapy | |
| RU2853818C9 (ru) | Способ лечения заболеваний с применением антагонистов GREMLIN1 | |
| RU2853818C1 (ru) | Способ лечения заболеваний с применением антагонистов GREMLIN1 | |
| Asavasupreechar et al. | SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicity | |
| WO2024249214A2 (en) | Anti-cd24 chimeric antigen receptor, compositions and methods | |
| HK40119904A (en) | Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251201 |